New Delhi: Access to genomic testing and matched treatments remains profoundly unequal within and between countries, according to a new commission by The Lancet Oncology. It has also identified substantial inequalities in cancer genetic testing research, reporting that only 2 per cent of biomarker-based cancer trials are conducted in low- and middle-income countries (LMICs), compared…
We use cookies to personalise content, deliver relevant advertising, and understand how our journalism is read. Accept all cookies, or limit us to those essential for the site to work. See our Cookie Policy.